HUP0202645A2 - Fornulations for parenteral use of estramustine phosphate and albumin - Google Patents

Fornulations for parenteral use of estramustine phosphate and albumin

Info

Publication number
HUP0202645A2
HUP0202645A2 HU0202645A HUP0202645A HUP0202645A2 HU P0202645 A2 HUP0202645 A2 HU P0202645A2 HU 0202645 A HU0202645 A HU 0202645A HU P0202645 A HUP0202645 A HU P0202645A HU P0202645 A2 HUP0202645 A2 HU P0202645A2
Authority
HU
Hungary
Prior art keywords
estramustine phosphate
albumin
fornulations
parenteral use
human albumin
Prior art date
Application number
HU0202645A
Other languages
Hungarian (hu)
Inventor
Giovanni Buzzi
Paolo Colombo
Alessandro Martini
Lorena Muggetti
Original Assignee
Pharmacia & Upjohn S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918779.1A external-priority patent/GB9918779D0/en
Priority claimed from IT99MI001998 external-priority patent/IT1313629B1/en
Application filed by Pharmacia & Upjohn S.P.A. filed Critical Pharmacia & Upjohn S.P.A.
Publication of HUP0202645A2 publication Critical patent/HUP0202645A2/en
Publication of HUP0202645A3 publication Critical patent/HUP0202645A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány parenteralisan elfogadható hordozót vagy hígítót és humánalbuminnal összekevert ösztramusztin-foszfátot tartalmazógyógyszerkészítményekre vonatkozik, amelyekben az ösztramusztin-foszfát és a humán albumin tömegaránya körülbelül 1:5 és körülbelül1:0,3 közötti értékű. ÓThe invention relates to pharmaceutical compositions comprising a parenterally acceptable carrier or diluent and estramustine phosphate mixed with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is between about 1:5 and about 1:0.3. HE

HU0202645A 1999-08-09 2000-08-03 Fornulations for parenteral use of estramustine phosphate and albumin HUP0202645A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9918779.1A GB9918779D0 (en) 1999-08-09 1999-08-09 Formulations for parenteral use of estramustine phosphate and albumin
IT99MI001998 IT1313629B1 (en) 1999-09-27 1999-09-27 New pharmaceutical compositions comprising estramustine phosphate and human albumin, useful for treating cancer e.g. prostate, breast, lung, pancreatic, colorectal, ovarian or brain cancer or melanoma
PCT/EP2000/007678 WO2001010446A2 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin

Publications (2)

Publication Number Publication Date
HUP0202645A2 true HUP0202645A2 (en) 2002-12-28
HUP0202645A3 HUP0202645A3 (en) 2004-06-28

Family

ID=26315835

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202645A HUP0202645A3 (en) 1999-08-09 2000-08-03 Fornulations for parenteral use of estramustine phosphate and albumin

Country Status (17)

Country Link
EP (1) EP1206266A2 (en)
JP (1) JP2003506408A (en)
KR (1) KR20020019967A (en)
CN (1) CN1511037A (en)
AU (1) AU6280900A (en)
BR (1) BR0013276A (en)
CA (1) CA2380312A1 (en)
CZ (1) CZ2002376A3 (en)
EA (1) EA200200234A1 (en)
HU (1) HUP0202645A3 (en)
IL (1) IL147745A0 (en)
MX (1) MXPA02001395A (en)
NO (1) NO20020631D0 (en)
NZ (1) NZ517632A (en)
PL (1) PL353406A1 (en)
SK (1) SK1782002A3 (en)
WO (1) WO2001010446A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426450B1 (en) * 2002-03-16 2004-04-13 박래옥 Anticancer Composition Comprising Citric acid, Albumin And Zinc
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
KR101198346B1 (en) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 Regeneration of chromatographic stationary phases
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
DE102006024528A1 (en) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg New formulation of a cytostatic, especially cis-platin, oriented on tumor physiology

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (en) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst Fine particle having guided missile action and slow-releasing function of carcinostatic agent
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
NZ517632A (en) 2004-02-27
WO2001010446A2 (en) 2001-02-15
NO20020631L (en) 2002-02-08
NO20020631D0 (en) 2002-02-08
EP1206266A2 (en) 2002-05-22
IL147745A0 (en) 2002-08-14
EA200200234A1 (en) 2002-06-27
PL353406A1 (en) 2003-11-17
CA2380312A1 (en) 2001-02-15
CN1511037A (en) 2004-07-07
KR20020019967A (en) 2002-03-13
BR0013276A (en) 2004-08-03
MXPA02001395A (en) 2002-08-12
HUP0202645A3 (en) 2004-06-28
SK1782002A3 (en) 2002-05-09
AU6280900A (en) 2001-03-05
WO2001010446A3 (en) 2001-05-25
JP2003506408A (en) 2003-02-18
CZ2002376A3 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
HK1026909A1 (en) Substituted phenyl derivatives, their preparation and use
PT1453512E (en) ACETYLENE DERIVATIVES HAVING ANTAGONISTIC ACTIVITY OF MGLUR 5
SE9702001D0 (en) Novel compounds
CA2135751A1 (en) 4-Mercaptoacetylamino-[2] Benzazepinone(3) Derivatives, and Use as Enkephalinase Inhibitors
CA2352505A1 (en) Epothilone derivatives and their use as antitumor agents
EP2292632A3 (en) Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HUT67742A (en) Phosphono-oxymethyl-ethers of taxane derivatives
CA2338600A1 (en) Novel thiazolopyrimidine compounds
HK1002017A1 (en) Lyospheres comprising gonadotropin
CA2388476A1 (en) Bicyclic imidazo-5-yl-amine derivatives
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
AU2002365646A1 (en) Novel proteins with il-6 inhibiting activity
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
CA2362698A1 (en) Resorcinol derivatives
BG105539A (en) Eletriptan hydrobromide monohydrate
HUP0202729A2 (en) Compositions for parenteral use of estramustine phosphate and amino acids
HUP0202645A2 (en) Fornulations for parenteral use of estramustine phosphate and albumin
MXPA04001419A (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease.
MX9604762A (en) Novel sulfonamides and process for the preparation thereof.
WO2003020209A3 (en) Processes for the production of alpha-difluoromethyl ornithine (dfmo)
CA2434187A1 (en) Androgenic 7-substituted 11-halogenated steroids
BG106151A (en) Pharmaceutical complex
AU4511299A (en) Imidazotriazolopyrimidines used as a drug having an adenosine antagonist activity